Skip to main content

Table 8 Interaction of all examined markers with paclitaxel treatment in terms of DFS and OS

From: alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies

 

DFS

OS

 

HR

95% CI

Wald’s p

HR

95% CI

Wald’s p

alphaB-crystallin * Treatment

  

0.72

  

0.75

alphaB-crystallin neg vs. pos in non-paclitaxel treated

1.21

0.48-3.01

 

0.88

0.35-2.23

 

alphaB-crystallin neg vs. pos in paclitaxel treated

0.81

0.53-1.24

 

0.60

0.38-0.97

 

Non-paclitaxel treated vs. paclitaxel treated in alphaB-crystallin neg

1.23

0.92-1.63

 

1.35

0.97-1.86

 

Non-paclitaxel treated vs. paclitaxel treated in alphaB-crystallin pos

0.82

0.31-2.17

 

0.93

0.35-2.47

 

BRCA1 * Treatment

  

0.55

  

0.99

BRCA1 neg vs. pos in non-paclitaxel treated

1.43

0.34-5.91

 

1.01

0.24-4.20

 

BRCA1 neg vs. pos in paclitaxel treated

0.96

0.61-1.49

 

1.02

0.59-1.77

 

Non-paclitaxel treated vs. paclitaxel treated in BRCA1 neg

1.19

0.90-1.58

 

1.29

0.94-1.78

 

Non-paclitaxel treated vs. paclitaxel treated in BRCA1 pos

0.79

0.18-3.43

 

1.31

0.29-5.85

 

BRCA1 * Treatment

  

0.37

  

0.48

BRCA1 WT vs. mut in non-paclitaxel treated1

.

.

 

.

.

 

BRCA1 WT vs. mut in paclitaxel treated

0.61

0.21-1.76

 

0.64

0.19-2.17

 

Non-paclitaxel treated vs. paclitaxel treated in BRCA1 WT

0.76

0.25-2.25

 

0.29

0.06-1.37

 

Non-paclitaxel treated vs. paclitaxel treated in BRCA1 mut1

.

.

 

.

.

 

p53 * Treatment

  

0.35

  

0.58

p53 neg vs. pos in non-paclitaxel treated

1.06

0.61-1.84

 

0.94

0.50-1.78

 

p53 neg vs. pos in paclitaxel treated

0.80

0.63-1.02

 

0.77

0.58-1.03

 

Non-paclitaxel treated vs. paclitaxel treated in p53 neg

1.36

0.82-2.23

 

1.37

0.76-2.47

 

Non-paclitaxel treated vs. paclitaxel treated in p53 pos

1.02

0.72-1.43

 

1.13

0.77-1.65

 
  1. *: interaction; 1: There were no patients with BRCA1 mutations in the non-paclitaxel treated group.
  2. HR, hazard ratio; CI, confidence interval; pos, positive; neg, negative; mut, mutated; WT, wild-type.